Literature DB >> 14288185

CLINICAL STUDIES OF DICHLOROMETHOTREXATE (NSC 29630).

E FREI, C L SPURR, C O BRINDLEY, O SELAWRY, J F HOLLAND, D P RALL, L R WASSERMAN, B HOOGSTRATEN, B I SHNIDER, O R MCINTYRE, L B MATTHEWS, S P MILLER.   

Abstract

Entities:  

Keywords:  AMINOPTERIN; DOGS; FOLIC ACID ANTAGONISTS; HODGKIN'S DISEASE; LEUKEMIA; LEUKEMIA, EXPERIMENTAL; LYMPHOMA; LYMPHOSARCOMA; METHOTREXATE; MICE; NEOPLASM THERAPY; NEOPLASMS, EXPERIMENTAL; PHARMACOLOGY; RATS; TOXICOLOGIC REPORT

Mesh：

Substances：

Year:  1965        PMID： 14288185     DOI： 10.1002/cpt196562160

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  6 in total

1.  Factors causing dose variability in drug administration.

Authors:  R Demicheli; A Jirillo; G Bonciarelli; F Lonardi; M Pradella; M Balli
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 2.  High dose chemotherapy with autologous marrow rescue in the treatment of resistant solid tumors.

Authors:  C F LeMaistre; W A Knight
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

3.  Evaluation of weekly escalating doses of dichloromethotrexate in patients with hepatocellular carcinoma and other solid tumors.

Authors:  W J Tester; R C Donehower; J L Eddy; C E Myers; D C Ihde
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 4.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

Review 5.  Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity.

Authors:  W E Evans
Journal:  Blut       Date:  1988-06

Review 6.  Drug Combination in Cancer Treatment-From Cocktails to Conjugated Combinations.

Authors:  Yosi Gilad; Gary Gellerman; David M Lonard; Bert W O'Malley
Journal:  Cancers (Basel)       Date:  2021-02-07       Impact factor: 6.639
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.